Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 11, 2017. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's ShareReward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Type | Instrument | Price per Share | Total Volume per Executive |
|---|---|---|---|
| Acquisition (ShareReward Plan) | Ordinary Shares (25 pence each) | £16.4378 | 16 Shares |
Each transaction consisted of 8 partnership shares and 8 matching shares.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine equity compensation transactions for nine senior executives on a single date.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Transaction Date: All reported transactions occurred on April 11, 2017.
- Executives Involved: Ms E Walmsley (CEO), Mr R G Connor, Mr S Dingemans (CFO), Mr N Hirons, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, and Mrs V A Whyte (Company Secretary).
- Transaction Nature: All were acquisitions of ordinary shares via the ShareReward Plan, not open market purchases or sales.
- Market: Transactions were conducted on the London Stock Exchange (XLON).
- Financial Impact: The total volume per executive (16 shares) is negligible relative to the company's total share capital and does not impact liquidity or debt metrics.